NEW YORK – Bruker said Wednesday that it has acquired Munich-based molecular interactions analysis company Dynamic Biosensors for an undisclosed amount.
Bruker highlighted Dynamic Biosensors' HelixCyto single-cell interaction cytometry technology and said the acquisition will bolster its biophysical portfolio for the analysis of molecular interactions and kinetics.
Dynamic Biosensors' HelixCyto technology allows researchers to make kinetic measurements directly on cells using single-cell interaction cytometry (scIC). Its Helix systems use the company's SwitchSense technology, where DNA nanolevers bind molecules of interest on a chip surface, allowing researchers to study their size, binding behavior, and kinetics, as well as conformational changes.
Bruker said it plans to combine these technologies with its Surface Plasmon Resonance (SPR) portfolio to provide a range of tools for studying intermolecular and molecule-cell interactions as part of drug discovery research.
"This strategic acquisition enhances Bruker’s position in the pharma and biotech industries by combining the cutting-edge Dynamic Biosensors instruments and Bruker’s leading high-throughput SPR portfolio, establishing a new technology leader in biosensors with a differentiated offering," Meike Hamester, VP of Bruker Biosensors, said in a statement.
Bruker said it expects Dynamic Biosensors to contribute revenues of greater than $5 million in 2025.